Q2 2026 saw strong revenue growth, driven by proprietary products and the successful integration of LUMRYZ. The orexin pipeline advanced with positive clinical data, while commercial execution and expanded access for key brands support long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.